Morgan Stanley’s Novo Integrated Sciences, Inc. Common Stock NVOS Stock Holding History

Morgan Stanley’s Portfolio NVOS Stock Details NVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5	Closed	-$1	–	8246
2024 Q3	$1	Hold	5	–	–	﹤0.01%	7927
2024 Q2	$4	Hold	5	–	–	﹤0.01%	7818
2024 Q1	$2	Sell	5 -5	-50%	-$3	﹤0.01%	7807
2023 Q4	$8	Buy	10 +5	+100%	+$10	﹤0.01%	7790
2023 Q3	$15	Hold	5	–	–	﹤0.01%	7549
2023 Q2	$7	Hold	5	–	–	﹤0.01%	7618
2023 Q1	$6	Buy	5 +3	+150%	+$4	﹤0.01%	7683
2022 Q4	$4	Buy	+2	New	+$7	﹤0.01%	7842
2021 Q3	–	Sell	-11,467	Closed	-$288K	–	8081
2021 Q2	$288K	Buy	+11,467	New	+$286K	﹤0.01%	5838

Other funds holding NVOS

ACT Advisors Asheville, North Carolina $301M AUM 23.36% 1-Year Est. Return

Morgan Stanley's NVOS Position: Q4 2024 in Review

Morgan Stanley sold out of Novo Integrated Sciences, Inc. Common Stock (NVOS) in Q4 2024, closing a stake of 5 shares — an estimated $1 sold.

Morgan Stanley first reported a position in NVOS in Q2 2021 and held it in 9 quarters. The position peaked at $288K in Q2 2021. 1 fund tracked by Wall St. Rank holds NVOS as of Q4 2024.

Morgan Stanley reported no remaining Novo Integrated Sciences, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Morgan Stanley sold 5 Novo Integrated Sciences, Inc. Common Stock shares in Q4 2024, an estimated $1.
Morgan Stanley first reported a position in Novo Integrated Sciences, Inc. Common Stock in Q2 2021 and held it in 9 quarters.
Morgan Stanley's Novo Integrated Sciences, Inc. Common Stock position peaked at $288K in Q2 2021.
1 fund tracked by Wall St. Rank held Novo Integrated Sciences, Inc. Common Stock as of Q4 2024.

Based on Morgan Stanley's 13F filing for Q4 2024, filed 14 Feb 2025.